Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05063435 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiovascular Structure and Function in the Mucopolysaccharidoses

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 7, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Notable Primary completion date: Oct 31, 2024 to Jun 30, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Mar 31, 2025 to Jun 30, 2026
    • Site details revised
    v4
  2. Minor Re-verified, no change to tracked fieldsv3
  3. Minor Start date changed from estimate of Nov 1, 2021 to Oct 13, 2021v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study's investigators previously demonstrated the potential utility of non-invasive carotid ultrasonography to calculate carotid intima media thickness (cIMT) and stiffness (as measured by the three parameters, carotid cross-sectional distensibility \[cCSD\], carotid cross-sectional compliance \[cCSC\], and carotid incremental elastic modulus \[cIEM\]) in people with mucopolysaccharidoses (MPS). Investigators also studied arterial gene expression in animal models of MPS, and identified upregulation of a number of markers potentially tied to atherosclerosis and inflammation. These include the atherosclerotic marker known as Clusterin (CLU), Cathepsin S, Elastin, and the inflammatory cytokines interleukin 1-α, interleukin 1-β, interleukin 2, and interleukin 6. Other studies have identified elevation in circulating tumor necrosis factor-α correlating with pain and physical disability in certain mucopolysaccharidoses. Since these studies are cross sectional, and not longitudinal, this study aims to annually measure these previously studied biomarkers (carotid measurements, circulating cytokines, cathepsin S, elastin, and CLU) in a large cohort of MPS patients. This study is a 3-year, prospective, anonymized, longitudinal assessment of cardiovascular structure, function, and circulating biomarkers in patients with mucopolysaccharidoses.
Trial Details
NCT Number NCT05063435
Lead Sponsor Children's Hospital of Orange County
Collaborators: Ultragenyx Pharmaceutical Inc
Conditions
(from sponsor)
Mucopolysaccharidoses, Carotid Disease, Cardiac Disease, Inflammation
Related terms Heart Diseases, Inflammation, Mucopolysaccharidoses
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov